Abstract:Previous meta‐analyses have generated inconsistent summary estimates for progestogen supplementation effects on live birth for women with threatened or recurrent miscarriage. To assess this, we conducted a meta‐analysis and found an increase in the likelihood of a live birth with progestogen supplementation, most convincing in those with prior miscarriage Introduction Clinical practice guidelines provide inconsistent recommendations regarding progestogen supplementation for threatened and recurrent miscarriage. We conducted a systematic review and meta‐analysis to assess the effectiveness and safety of progestogens for these patients. Material and methods We searched Medline, Embase, and Cochrane Central Registry of Controlled Trials up to October 6, 2023 for randomized control trials (RCTs) comparing progestogen supplementation to placebo or no treatment for pregnant women with threatened or recurrent miscarriage. We assessed the risk of bias using a modified version of the Cochrane risk‐of‐bias tool and the certainty of evidence using the GRADE approach. Results Of 15 RCTs (6616 pregnancies) reporting on threatened or recurrent miscarriage, 12 (5610 pregnancies) reported on threatened miscarriage with or without a prior history of miscarriage. Results indicated that progesterone probably increases live births (relative risk (RR) 1.04, 95% confidence interval (CI) 0.99–1.10, absolute increase 3.1%, moderate certainty). Of these RCTs, three (1973 pregnancies) reporting on threatened miscarriage with a prior history of miscarriage indicated that progesterone possibly increases live births (RR 1.06, 95% CI: 0.97–1.16, absolute increase 4.4%; low certainty), while four (2540 pregnancies) reporting on threatened miscarriage and no prior miscarriage left the effect very uncertain (RR 1.02, 95% CI: 0.96–1.10, absolute increase 1.7%; very low certainty). Three trials reporting on 1006 patients with a history of two or more prior miscarriages indicated progesterone probably increases live births (RR 1.08, 95% CI: 0.98–1.19, absolute increase 5.7%, moderate certainty). Six RCTs that reported on 2979 patients with at least one prior miscarriage indicated that progesterone probably increases live births (RR 1.07, 95% CI: 1.01–1.13, absolute increase 5.0%; moderate certainty). Progesterone probably has little or no effect on congenital anomalies (RR 1.06, 95% CI: 0.76–1.48, absolute increase 0.1%; moderate certainty), and other serious adverse pregnancy events (RR 1.07, 95% CI: 0.83–1.40, absolute increase 0.2%, moderate certainty). Conclusions In women at increased risk of pregnancy loss, progestogens probably increase live births without increasing adverse maternal and neonatal events. It remains possible that the benefit is restricted to those with prior miscarriages.

Progesterone in Pregnancy: Evidence-Based Strategies to Reduce Miscarriage and Enhance Assisted Reproductive Technology

Can Single Progesterone Concentration Predict Miscarriage in Early Pregnant Women with Threatened Miscarriage: a Systematic Review and Meta-Analysis

Pregnancy-related complications and perinatal outcomes following progesterone supplementation before 20 weeks of pregnancy in spontaneously achieved singleton pregnancies: a systematic review and meta-analysis

A Clinical Study on the Level of Serum Low Progesterone about Luteal Phase Support for Partial Vaginal Delivery in Assisted Reproductive Technology

New progress on progesterone maintaining pregnancy and preventing obstetric complications

Exploring Progesterone Deficiency in First-Trimester Miscarriage and the Impact of Hormone Therapy on Foetal Development: A Scoping Review

Progestogens in women with threatened miscarriage or recurrent miscarriage: A meta‐analysis

Novel Approach Using Serum Progesterone As a Triage to Guide Management of Patients with Threatened Miscarriage: a Prospective Cohort Study

The effect of progesterone supplementation for luteal phase support in natural cycle frozen embryo transfer: a systematic review and meta-analysis based on randomized controlled trials

Challenge of development of assisted reproduction technology on perinatal medicine and health of offspring

Progestogen for the prevention of preterm birth

Comparison of the effect of dydrogesterone and natural micronized progesterone for luteal-phase support in assisted reproductive technology cycles: A single-blind randomized clinical trial study

Progesterone for the Prevention of Preterm Birth - an Update of Evidence-Based Indications

Effectiveness Of Progesterone, Cerclage And Pessary For Preventing Preterm Birth In Singleton Pregnancies: A Systematic Review And Network Meta-Analysis

Effects of vaginal progesterone and placebo on preterm birth and antenatal outcomes in women with singleton pregnancies and short cervix on ultrasound: a meta-analysis

Peri-conceptional progesterone treatment in women with unexplained recurrent miscarriage: a randomized double-blind placebo-controlled trial

The Safety of Progesterone and 17-Hydroxyprogesterone Caproate Administration for the Prevention of Preterm Birth: An Evidence-Based Assessment

Serum concentrations of luteinizing hormone and progesterone in ovum recipients: their relationship with pregnancy and miscarriage

Reproductive outcomes in fresh transfer cycles and antagonists with premature luteinizing and/or progesterone surge: a single center retrospective cohort study

Effectiveness of Progesterone, Cerclage and Pessary for Preventing Preterm Birth in Singleton Pregnancies: a Systematic Review and Network Meta‐analysis

The Effect of Progesterone Elevation on the Day of Trigger Administration: A Review of the Literature